1
|
Duan M, Zhou D, Ke J, Chen Y, Wu W, Li Y, Ren J, Wang L, Zhang Z, Wang C. Dual targetable drug delivery system based on cell membrane camouflaged liposome for enhanced tumor targeting and improved anti-tumor efficiency. Colloids Surf B Biointerfaces 2024; 238:113892. [PMID: 38581834 DOI: 10.1016/j.colsurfb.2024.113892] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2023] [Revised: 03/29/2024] [Accepted: 04/02/2024] [Indexed: 04/08/2024]
Abstract
Receptor and ligand binding mediated targeted drug delivery systems (DDS) sometimes fail to target to tumor sites, and cancer cell membrane (CCM) coating can overcome the dilemma of immune clearance and nonspecific binding of DDS in vivo. In order to enhance the targeting ability and improve the anti-tumor effect, a dual targeting DDS was established based on U87MG CCM mediated homologous targeting and cyclic peptide RGD mediated active targeting. The DDS was prepared by coating RGD doped CCM onto doxorubicin (DOX) loaded liposomes. The homologous and active dual targeting ability endowed the DDS (RGD-CCM-LP-DOX) exhibited superior cancer cell affinity, improved tissue distribution and enhanced anti-tumor effects. In vivo pharmacodynamic studies revealed that RGD-CCM-LP-DOX exhibited superior therapeutic effect compared with homologous targeting CCM-LP-DOX and non-targetable LP-DOX injection. H&E staining, Ki 67 staining and TUNEL staining confirmed that RGD-CCM-LP-DOX not only increased anti-tumor efficacy, but also reduced tissue toxicity by changing the distribution in vivo. The experimental results showed that the RGD doped CCM camouflaged liposome DDS is a better choice for chemotherapeutics delivery.
Collapse
Affiliation(s)
- Meitao Duan
- School of Pharmacy, Xiamen Medical College, Xiamen 361023, PR China; Research Center for Sustained and Controlled Release Formulations, Xiamen Medical College, Xiamen 361023, PR China
| | - Dan Zhou
- School of Pharmacy, Xiamen Medical College, Xiamen 361023, PR China; Institute of Respiratory Diseases, Xiamen Medical College, Xiamen 361023, PR China
| | - Junfang Ke
- School of Pharmacy, Fujian Medical University, Fuzhou 350108, PR China
| | - Yan Chen
- Department of Pharmacy, Xiang'an hospital of Xiamen University, Xiamen 361023, PR China
| | - Wenfeng Wu
- School of Pharmacy, Xiamen Medical College, Xiamen 361023, PR China
| | - Yue Li
- School of Pharmacy, Fujian Medical University, Fuzhou 350108, PR China
| | - Jungang Ren
- School of Pharmacy, Xiamen Medical College, Xiamen 361023, PR China
| | - Li Wang
- School of Pharmacy, Xiamen Medical College, Xiamen 361023, PR China
| | - Zhiqiang Zhang
- School of Pharmacy, Xiamen Medical College, Xiamen 361023, PR China; Research Center for Sustained and Controlled Release Formulations, Xiamen Medical College, Xiamen 361023, PR China.
| | - Chen Wang
- School of Pharmacy, Xiamen Medical College, Xiamen 361023, PR China; Research Center for Sustained and Controlled Release Formulations, Xiamen Medical College, Xiamen 361023, PR China.
| |
Collapse
|
2
|
Zhang J, Liu W, Liu Y, Zhang J, Gao P, Zheng L, Xu F, Jin G, Tang BZ. A New Strategy to Elevate Absorptivity of AIEgens for Intensified NIR-II Emission and Synergized Multimodality Therapy. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2023; 35:e2306616. [PMID: 37489377 DOI: 10.1002/adma.202306616] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Indexed: 07/26/2023]
Abstract
High-efficiency absorptivity is crucial for the construction of high-performance luminescent materials, especially the long-wavelength near-infrared II (NIR-II) materials; thus seeking an efficient and universal strategy to elevate the absorptivity is extremely important but is still an intractable challenge. In this work, a simple but efficient design strategy is discovered, involving the introduction of gold(I) unit that could effectively elevate the absorptivity of aggregation-induced-emission luminogens (AIEgens). As a result of the efficient elevation of absorptivity, the representative AIE-active TBTP-Au shows more superior NIR-II (1220 nm) luminescence, much higher photothermal conversion efficiency, and unique intracellular reactive oxygen species (ROS) generating ability compared with that of the TBTP ligand. Taking advantage of these improvements, the fabricated tumor-targeting TBTP-Au-cRGD nanoparticles achieve specific NIR-II tumorous imaging in vivo and exert high-efficiency cancer therapy via the synergistic chemotherapy and photothermal therapy. Thus, this work provides a new and efficient strategy to construct high-absorption luminescent materials and demonstrates the great potential of gold(I)-based AIEgens as multifunctional theranostic agents.
Collapse
Affiliation(s)
- Jing Zhang
- Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China
| | - Wenjing Liu
- The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, 710048, China
| | - Yangjing Liu
- The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, 710048, China
| | - Jianyu Zhang
- Department of Chemistry, Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction and Institute for Advanced Study, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, 999077, China
| | - Pengfei Gao
- Key Laboratory of Luminescence Analysis and Molecular Sensing (Southwest University) Ministry of Education, College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, China
| | - Lei Zheng
- Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China
| | - Feng Xu
- The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, 710048, China
| | - Guorui Jin
- The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, 710048, China
| | - Ben Zhong Tang
- Department of Chemistry, Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction and Institute for Advanced Study, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, 999077, China
- School of Science and Engineering, Shenzhen Institute of Aggregate Science and Technology, The Chinese University of Hong Kong, Shenzhen, Guangdong, 518172, China
| |
Collapse
|
3
|
Tincu (Iurciuc) CE, Andrițoiu CV, Popa M, Ochiuz L. Recent Advancements and Strategies for Overcoming the Blood-Brain Barrier Using Albumin-Based Drug Delivery Systems to Treat Brain Cancer, with a Focus on Glioblastoma. Polymers (Basel) 2023; 15:3969. [PMID: 37836018 PMCID: PMC10575401 DOI: 10.3390/polym15193969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2023] [Revised: 09/23/2023] [Accepted: 09/26/2023] [Indexed: 10/15/2023] Open
Abstract
Glioblastoma multiforme (GBM) is a highly aggressive malignant tumor, and the most prevalent primary malignant tumor affecting the brain and central nervous system. Recent research indicates that the genetic profile of GBM makes it resistant to drugs and radiation. However, the main obstacle in treating GBM is transporting drugs through the blood-brain barrier (BBB). Albumin is a versatile biomaterial for the synthesis of nanoparticles. The efficiency of albumin-based delivery systems is determined by their ability to improve tumor targeting and accumulation. In this review, we will discuss the prevalence of human glioblastoma and the currently adopted treatment, as well as the structure and some essential functions of the BBB, to transport drugs through this barrier. We will also mention some aspects related to the blood-tumor brain barrier (BTBB) that lead to poor treatment efficacy. The properties and structure of serum albumin were highlighted, such as its role in targeting brain tumors, as well as the progress made until now regarding the techniques for obtaining albumin nanoparticles and their functionalization, in order to overcome the BBB and treat cancer, especially human glioblastoma. The albumin drug delivery nanosystems mentioned in this paper have improved properties and can overcome the BBB to target brain tumors.
Collapse
Affiliation(s)
- Camelia-Elena Tincu (Iurciuc)
- Department of Natural and Synthetic Polymers, “Cristofor Simionescu” Faculty of Chemical Engineering and Protection of the Environment, “Gheorghe Asachi” Technical University, 73, Prof. Dimitrie Mangeron Street, 700050 Iasi, Romania;
- Department of Pharmaceutical Technology, Faculty of Pharmacy, “Grigore T. Popa” University of Medicine and Pharmacy, 16, University Street, 700115 Iasi, Romania;
| | - Călin Vasile Andrițoiu
- Apitherapy Medical Center, Balanesti, Nr. 336-337, 217036 Gorj, Romania;
- Specialization of Nutrition and Dietetics, Faculty of Pharmacy, Vasile Goldis Western University of Arad, Liviu Rebreanu Street, 86, 310045 Arad, Romania
| | - Marcel Popa
- Department of Natural and Synthetic Polymers, “Cristofor Simionescu” Faculty of Chemical Engineering and Protection of the Environment, “Gheorghe Asachi” Technical University, 73, Prof. Dimitrie Mangeron Street, 700050 Iasi, Romania;
- Faculty of Dental Medicine, “Apollonia” University of Iasi, 11, Pacurari Street, 700511 Iasi, Romania
- Academy of Romanian Scientists, 3 Ilfov Street, 050045 Bucharest, Romania
| | - Lăcrămioara Ochiuz
- Department of Pharmaceutical Technology, Faculty of Pharmacy, “Grigore T. Popa” University of Medicine and Pharmacy, 16, University Street, 700115 Iasi, Romania;
| |
Collapse
|
4
|
Challenges in Preparation of Albumin Nanoparticle-Based Radiopharmaceuticals. MOLECULES (BASEL, SWITZERLAND) 2022; 27:molecules27238596. [PMID: 36500689 PMCID: PMC9740174 DOI: 10.3390/molecules27238596] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/21/2022] [Revised: 11/22/2022] [Accepted: 12/01/2022] [Indexed: 12/12/2022]
Abstract
Albumin nanocolloids have been used as radiopharmaceuticals for more than 40 years. Their main use is in lymphoscintigraphy and the detection of the sentinel lymph node as part of the surgical treatment of a variety of solid tumours. The main licensed products are labelled with the gamma emitter technetium-99m. Recently, two analogues labelled with positron emitters have been reported, using gallium-68 and zirconium-89. For about 10 years, there has been interest in dual-modal agents with both radioactive and fluorescent labels to improve the localisation of the sentinel lymph node. Indocyanine green (ICG) has been the most widely used fluorescent label, largely due to its availability as a licensed agent and its ease of application. The further development of alternative radiolabels or improved fluorescent tags will require investment in the development and licensing. There is also a vast potential for the targeting of albumin nanocolloids using existing strategies, which could be promising for the development of both diagnostic and therapeutic agents.
Collapse
|
5
|
Jain A, Singh SK, Arya SK, Kundu SC, Kapoor S. Protein Nanoparticles: Promising Platforms for Drug Delivery Applications. ACS Biomater Sci Eng 2018; 4:3939-3961. [DOI: 10.1021/acsbiomaterials.8b01098] [Citation(s) in RCA: 114] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Annish Jain
- Department of Biotechnology, University Institute of Engineering and Technology, Panjab University, Chandigarh 160 014, India
| | - Sumit K. Singh
- Department of Biotechnology, University Institute of Engineering and Technology, Panjab University, Chandigarh 160 014, India
| | - Shailendra K. Arya
- Department of Biotechnology, University Institute of Engineering and Technology, Panjab University, Chandigarh 160 014, India
| | - Subhas C. Kundu
- 3B’s Research Group, I3Bs − Biomaterials, Biodegradables and Biomimetics, University of Minho, AvePark, 4805-017 Barco, Guimarães, Portugal
| | - Sonia Kapoor
- Department of Biotechnology, University Institute of Engineering and Technology, Panjab University, Chandigarh 160 014, India
- Amity Institute of Molecular Medicine and Stem Cell Research, Amity University, Noida 201 313, Uttar Pradesh, India
| |
Collapse
|
6
|
Huang R, Li J, Kebebe D, Wu Y, Zhang B, Liu Z. Cell penetrating peptides functionalized gambogic acid-nanostructured lipid carrier for cancer treatment. Drug Deliv 2018; 25:757-765. [PMID: 29528244 PMCID: PMC6058566 DOI: 10.1080/10717544.2018.1446474] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2017] [Revised: 02/26/2018] [Accepted: 02/26/2018] [Indexed: 12/11/2022] Open
Abstract
Tumor-targeted delivery is considered a crucial component of current anticancer drug development and is the best approach to increase the efficacy and reduce the toxicity. Nanomedicine, particularly ligand-based nanoparticles have shown a great potential for active targeting of tumor. Cell penetrating peptide is one of the promising ligands in a targeted cancer therapy. In this study, the gambogic acid-loaded nanostructured lipid carrier (GA-NLC) was modified with two kinds of cell penetrating peptides (cRGD and RGERPPR). The GA-NLC was prepared by emulsification and solvent evaporation method and coupled with cRGD, RGERPPR, and combination cRGD and RGERPPR to form GA-NLC-cRGD, GA-NLC-RGE, and GA-NLC-cRGD/RGE, respectively. The formulations were characterized by their particle size and morphology, zeta potential, encapsulation efficiency, and differential scanning calorimetry. In vitro cytotoxicity and cellular uptake study of the formulations were performed against breast cancer cell (MDA-MB-231). Furthermore, in vivo biodistribution and antitumor activity of the formulations were determined by in vivo imaging and in tumor-bearing nude mice, respectively. The result of in vitro cytotoxicity study showed that GA-NLC-RGE exhibited a significantly higher cytotoxicity on MDA-MB-231 as compared with GA-NLC and GA-Sol. Similarly, RGE-Cou-6-NLC showed remarkably higher uptake by the cells than other NLCs over the incubation period. The in vivo imaging study has demonstrated that among the formulations, the RGE-decorated DiR-NLC were more accumulated in the tumor site. The in vivo antitumor activity revealed that RGE-GA-NLC inhibits the tumor growth more efficiently than other formulations. In conclusion, RGERPPR has a potential as an effective carrier in targeting drug delivery of anticancer agents.
Collapse
MESH Headings
- Absorption, Physiological
- Animals
- Antineoplastic Agents, Phytogenic/administration & dosage
- Antineoplastic Agents, Phytogenic/pharmacokinetics
- Antineoplastic Agents, Phytogenic/pharmacology
- Antineoplastic Agents, Phytogenic/therapeutic use
- Breast Neoplasms/drug therapy
- Breast Neoplasms/metabolism
- Breast Neoplasms/pathology
- Cell Line, Tumor
- Cell Survival/drug effects
- Cell-Penetrating Peptides/adverse effects
- Cell-Penetrating Peptides/chemistry
- Drug Carriers/administration & dosage
- Drug Carriers/pharmacokinetics
- Drug Carriers/pharmacology
- Drug Carriers/therapeutic use
- Drug Compounding
- Female
- Humans
- Mice, Inbred BALB C
- Mice, Nude
- Microscopy, Electron, Transmission
- Nanostructures/adverse effects
- Nanostructures/chemistry
- Nanostructures/ultrastructure
- Particle Size
- Random Allocation
- Surface Properties
- Tissue Distribution
- Tumor Burden/drug effects
- Xanthones/administration & dosage
- Xanthones/pharmacokinetics
- Xanthones/pharmacology
- Xanthones/therapeutic use
- Xenograft Model Antitumor Assays
Collapse
Affiliation(s)
- Rui Huang
- Tianjin State Key Laboratory of Modern Chinese Medicine, Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China
- Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China
| | - Jiawei Li
- Tianjin State Key Laboratory of Modern Chinese Medicine, Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China
- Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China
| | - Dereje Kebebe
- Tianjin State Key Laboratory of Modern Chinese Medicine, Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China
- Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China
- School of Pharmacy, Institute of Health Sciences, Jimma University, Jimma, Ethiopia
| | - Yumei Wu
- Tianjin State Key Laboratory of Modern Chinese Medicine, Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China
- Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China
| | - Bing Zhang
- Tianjin State Key Laboratory of Modern Chinese Medicine, Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China
- Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China
| | - Zhidong Liu
- Tianjin State Key Laboratory of Modern Chinese Medicine, Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China
- Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China
| |
Collapse
|
7
|
Xu B, Xu Y, Su G, Zhu H, Zong L. A multifunctional nanoparticle constructed with a detachable albumin outer shell and a redox-sensitive inner core for efficient siRNA delivery to hepatocellular carcinoma cells. J Drug Target 2018; 26:941-954. [PMID: 29564911 DOI: 10.1080/1061186x.2018.1455840] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Successful delivery of small interfering RNA (siRNA) into the cytoplasm of target cells relies on biocompatible and efficient vectors. In this study, a novel multifunctional core/shell nanoparticle [CS-SS-9R/BSA-c(RGDyK)] was developed to effectively deliver siVEGF to hepatocellular carcinoma cells (Bel-7402 cells). To improve the gene payload and transfection efficiency, a positively charged inner core (CS-SS-9R) was constructed by grafting nona-arginine (9R) onto chitosan (CS) using disulphide bonds. The negatively charged outer shell [BSA-c(RGDyK)] assembled on the surface of the inner core by electrostatic forces that shielded high cationic charges and provided improved targeting. The protein outer shell gradually detached from the inner core in the acidic lysosomal environment, leaving the cationic inner core exposed in order to escape from lysosomes. The nanoparticles were capable of delivering siVEGF into Bel-7402 cells via integrin receptor-mediated endocytosis. Successful lysosomal escape of the inner core and the rapid release of siVEGF into the cytoplasm resulted in a 78.9% decrease in VEGF expression and 81.2% inhibition of tumour cell proliferation. In conclusion, this nanoparticle is responsive to the intracellular environment and accurately delivered siRNA into the cytoplasm, providing a safe and highly efficient gene delivery strategy for cancer therapy.
Collapse
Affiliation(s)
- Bohui Xu
- a School of Pharmacy , China Pharmaceutical University , Nanjing , China.,b School of Pharmacy , Nantong University , Nantong , China
| | - Yan Xu
- b School of Pharmacy , Nantong University , Nantong , China
| | - Gaoxing Su
- b School of Pharmacy , Nantong University , Nantong , China
| | - Hongyan Zhu
- b School of Pharmacy , Nantong University , Nantong , China
| | - Li Zong
- a School of Pharmacy , China Pharmaceutical University , Nanjing , China
| |
Collapse
|
8
|
Nanoparticles and targeted drug delivery in cancer therapy. Immunol Lett 2017; 190:64-83. [PMID: 28760499 DOI: 10.1016/j.imlet.2017.07.015] [Citation(s) in RCA: 253] [Impact Index Per Article: 36.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2017] [Revised: 07/04/2017] [Accepted: 07/26/2017] [Indexed: 12/11/2022]
Abstract
Surgery, chemotherapy, radiotherapy, and hormone therapy are the main common anti-tumor therapeutic approaches. However, the non-specific targeting of cancer cells has made these approaches non-effective in the significant number of patients. Non-specific targeting of malignant cells also makes indispensable the application of the higher doses of drugs to reach the tumor region. Therefore, there are two main barriers in the way to reach the tumor area with maximum efficacy. The first, inhibition of drug delivery to healthy non-cancer cells and the second, the direct conduction of drugs into tumor site. Nanoparticles (NPs) are the new identified tools by which we can deliver drugs into tumor cells with minimum drug leakage into normal cells. Conjugation of NPs with ligands of cancer specific tumor biomarkers is a potent therapeutic approach to treat cancer diseases with the high efficacy. It has been shown that conjugation of nanocarriers with molecules such as antibodies and their variable fragments, peptides, nucleic aptamers, vitamins, and carbohydrates can lead to effective targeted drug delivery to cancer cells and thereby cancer attenuation. In this review, we will discuss on the efficacy of the different targeting approaches used for targeted drug delivery to malignant cells by NPs.
Collapse
|
9
|
Enhanced tumor targeting of cRGD peptide-conjugated albumin nanoparticles in the BxPC-3 cell line. Sci Rep 2016; 6:31539. [PMID: 27515795 PMCID: PMC4981853 DOI: 10.1038/srep31539] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2016] [Accepted: 07/21/2016] [Indexed: 12/23/2022] Open
Abstract
The emerging albumin nanoparticle brings new hope for the delivery of antitumor drugs. However, a lack of robust tumor targeting greatly limits its application. In this paper, cyclic arginine-glycine-aspartic-conjugated, gemcitabine-loaded human serum albumin nanoparticles (cRGD-Gem-HSA-NPs) were successfully prepared, characterized, and tested in vitro in the BxPC-3 cell line. Initially, 4-N-myristoyl-gemcitabine (Gem-C14) was formed by conjugating myristoyl to the 4-amino group of gemcitabine. Then, cRGD-HSA was synthesized using sulfosuccinimidyl-(4-N-maleimidomethyl)cyclohexane-1-carboxylate (Sulfo-SMCC) cross-linkers. Finally, cRGD-Gem-HSA-NPs were formulated based on the nanoparticle albumin-bound (nab) technology. The resulting NPs were characterized for particle size, zeta potential, morphology, encapsulation efficiency, and drug loading efficiency. In vitro cellular uptake and inhibition studies were conducted to compare Gem-HSA-NPs and cRGD-Gem-HSA-NPs in a human pancreatic cancer cell line (BxPC-3). The cRGD-Gem-HSA-NPs exhibited an average particle size of 160 ± 23 nm. The encapsulation rate and drug loading rate were approximately 83 ± 5.6% and 11 ± 4.2%, respectively. In vitro, the cRGD-anchored NPs exhibited a significantly greater affinity for the BxPC-3 cells compared to non-targeted NPs and free drug. The cRGD-Gem-HSA-NPs also showed the strongest inhibitory effect in the BxPC-3 cells among all the analyzed groups. The improved efficacy of cRGD-Gem-HSA-NPs in the BxPC-3 cell line warrants further in vivo investigations.
Collapse
|
10
|
Zhang K, Li P, He Y, Bo X, Li X, Li D, Chen H, Xu H. Synergistic retention strategy of RGD active targeting and radiofrequency-enhanced permeability for intensified RF & chemotherapy synergistic tumor treatment. Biomaterials 2016; 99:34-46. [PMID: 27209261 DOI: 10.1016/j.biomaterials.2016.05.014] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2016] [Revised: 05/06/2016] [Accepted: 05/09/2016] [Indexed: 12/22/2022]
Abstract
Despite gaining increasing attention, chelation of multiple active targeting ligands greatly increase the formation probability of protein corona, disabling active targeting. To overcome it, a synergistic retention strategy of RGD-mediated active targeting and radiofrequency (RF) electromagnetic field-enhanced permeability has been proposed here. It is validated that such a special synergistic retention strategy can promote more poly lactic-co-glycolic acid (PLGA)-based capsules encapsulating camptothecin (CPT) and solid DL-menthol (DLM) to enter and retain in tumor in vitro and in vivo upon exposure to RF irradiation, receiving an above 8 fold enhancement in HeLa retention. Moreover, the PLGA-based capsules can respond RF field to trigger the entrapped DLM to generate solid-liquid-gas (SLG) tri-phase transformation for enhancing RF ablation and CPT release. Therefore, depending on the enhanced RF ablation and released CPT and the validated synergistic retention effect, the inhibitory outcome for tumor growth has gained an over 10-fold improvement, realizing RF ablation & chemotherapy synergistic treatment against HeLa solid tumor, which indicates a significant promise in clinical RF ablation.
Collapse
Affiliation(s)
- Kun Zhang
- Department of Medical Ultrasound, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Yan-chang-zhong Road, Shanghai, 200072, PR China; Ultrasound Research and Education Institute, Tongji University School of Medicine, 301 Yan-hang-zhong Road, Shanghai, 200072, PR China
| | - Pei Li
- Department of Medical Ultrasound, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Yan-chang-zhong Road, Shanghai, 200072, PR China; Ultrasound Research and Education Institute, Tongji University School of Medicine, 301 Yan-hang-zhong Road, Shanghai, 200072, PR China
| | - Yaping He
- Department of Medical Ultrasound, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Yan-chang-zhong Road, Shanghai, 200072, PR China; Ultrasound Research and Education Institute, Tongji University School of Medicine, 301 Yan-hang-zhong Road, Shanghai, 200072, PR China
| | - Xiaowan Bo
- Department of Medical Ultrasound, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Yan-chang-zhong Road, Shanghai, 200072, PR China
| | - Xiaolong Li
- Department of Medical Ultrasound, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Yan-chang-zhong Road, Shanghai, 200072, PR China
| | - Dandan Li
- Department of Medical Ultrasound, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Yan-chang-zhong Road, Shanghai, 200072, PR China
| | - Hangrong Chen
- State Key Laboratory of High Performance Ceramics and Superfine Microstructures, Shanghai Institute of Ceramics, Chinese Academy of Sciences, 1295 Ding-Xi Road, Shanghai, 200050, PR China.
| | - Huixiong Xu
- Department of Medical Ultrasound, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Yan-chang-zhong Road, Shanghai, 200072, PR China; Ultrasound Research and Education Institute, Tongji University School of Medicine, 301 Yan-hang-zhong Road, Shanghai, 200072, PR China.
| |
Collapse
|
11
|
Yu X, Jin C. Application of albumin-based nanoparticles in the management of cancer. JOURNAL OF MATERIALS SCIENCE. MATERIALS IN MEDICINE 2016; 27:4. [PMID: 26610927 DOI: 10.1007/s10856-015-5618-9] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/22/2015] [Accepted: 11/04/2015] [Indexed: 06/05/2023]
Abstract
Over the past three decades, tremendous progress has been made in cancer prevention and treatment. Despite these advances, a substantial number of cancer cases experience early recurrence and metastases. Thus, the better management of cancer, especially developing more effective drugs for combating cancer cells, is an arduous task. Albumin-based nanoparticles are emerging as a promising approach to replace the traditional way of carrying therapeutic drugs to a tumor site. In this review, we describe the basic knowledge on albumin-based nanoparticles, recent progress of using albumin-based nanoparticles in the diagnosis and treatment of cancer, and the application of nanoparticle albumin bound (Nab) paclitaxel for the treatment of lung, breast and pancreatic cancer. Last but not least, we try to discuss future goals and perspectives in the field of drug delivery research, thereby facilitating the antitumor activity.
Collapse
Affiliation(s)
- Xinzhe Yu
- Department of Pancreatic Surgery, Huashan Hospital, Fudan University, Middle Urumqi Road 12#, Shanghai, 200040, China.
| | - Chen Jin
- Department of Pancreatic Surgery, Huashan Hospital, Fudan University, Middle Urumqi Road 12#, Shanghai, 200040, China.
| |
Collapse
|
12
|
Nanomedicine applied to translational oncology: A future perspective on cancer treatment. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2015; 12:81-103. [PMID: 26370707 DOI: 10.1016/j.nano.2015.08.006] [Citation(s) in RCA: 151] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/10/2015] [Revised: 07/17/2015] [Accepted: 08/27/2015] [Indexed: 01/08/2023]
Abstract
The high global incidence of cancer is associated with high rates of mortality and morbidity worldwide. By taking advantage of the properties of matter at the nanoscale, nanomedicine promises to develop innovative drugs with greater efficacy and less side effects than standard therapies. Here, we discuss both clinically available anti-cancer nanomedicines and those en route to future clinical application. The properties, therapeutic value, advantages and limitations of these nanomedicine products are highlighted, with a focus on their increased performance versus conventional molecular anticancer therapies. The main regulatory challenges toward the translation of innovative, clinically effective nanotherapeutics are discussed, with a view to improving current approaches to the clinical management of cancer. Ultimately, it becomes clear that the critical steps for clinical translation of nanotherapeutics require further interdisciplinary and international effort, where the whole stakeholder community is involved from bench to bedside. From the Clinical Editor: Cancer is a leading cause of mortality worldwide and finding a cure remains the holy-grail for many researchers and clinicians. The advance in nanotechnology has enabled novel strategies to develop in terms of cancer diagnosis and therapy. In this concise review article, the authors described current capabilities in this field and outlined comparisons with existing drugs. The difficulties in bringing new drugs to the clinics were also discussed.
Collapse
|
13
|
Implications of Protein- and Peptide-Based Nanoparticles as Potential Vehicles for Anticancer Drugs. ADVANCES IN PROTEIN CHEMISTRY AND STRUCTURAL BIOLOGY 2015; 98:169-221. [DOI: 10.1016/bs.apcsb.2014.12.002] [Citation(s) in RCA: 88] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
14
|
Yousefpour P, Chilkoti A. Co-opting biology to deliver drugs. Biotechnol Bioeng 2014; 111:1699-716. [PMID: 24916780 PMCID: PMC4251460 DOI: 10.1002/bit.25307] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2014] [Revised: 05/30/2014] [Accepted: 06/05/2014] [Indexed: 01/17/2023]
Abstract
The goal of drug delivery is to improve the safety and therapeutic efficacy of drugs. This review focuses on delivery platforms that are either derived from endogenous pathways, long-circulating biomolecules and cells or that piggyback onto long-circulating biomolecules and cells. The first class of such platforms is protein-based delivery systems--albumin, transferrin, and fusion to the Fc domain of antibodies--that have a long-circulation half-life and are designed to transport different molecules. The second class is lipid-based delivery systems-lipoproteins and exosomes-that are naturally occurring circulating lipid particles. The third class is cell-based delivery systems--erythrocytes, macrophages, and platelets--that have evolved, for reasons central to their function, to exhibit a long life-time in the body. The last class is small molecule-based delivery systems that include folic acid. This article reviews the biology of these systems, their application in drug delivery, and the promises and limitations of these endogenous systems for drug delivery.
Collapse
Affiliation(s)
- Parisa Yousefpour
- Department of Biomedical Engineering, Duke University, Durham, North Carolina, 27708
| | | |
Collapse
|
15
|
Xing H, Zheng X, Ren Q, Bu W, Ge W, Xiao Q, Zhang S, Wei C, Qu H, Wang Z, Hua Y, Zhou L, Peng W, Zhao K, Shi J. Computed tomography imaging-guided radiotherapy by targeting upconversion nanocubes with significant imaging and radiosensitization enhancements. Sci Rep 2014; 3:1751. [PMID: 23624542 PMCID: PMC3638198 DOI: 10.1038/srep01751] [Citation(s) in RCA: 77] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2012] [Accepted: 04/15/2013] [Indexed: 12/20/2022] Open
Abstract
The clinical potentials of radiotherapy could not be achieved completely because of the inaccurate positioning and inherent radioresistance of tumours. In this study, a novel active-targeting upconversion theranostic agent (arginine-glycine-aspartic acid-labelled BaYbF5: 2% Er3+ nanocube) was developed for the first time to address these clinical demands. Heavy metal-based nanocubes (~10 nm) are potential theranostic agents with bifunctional features: computed tomography (CT) contrast agents for targeted tumour imaging and irradiation dose enhancers in tumours during radiotherapy. Remarkably, they showed low toxicity and excellent performance in active-targeting CT imaging and CT imaging-guided radiosensitizing therapy, which could greatly concentrate and enlarge the irradiation dose deposition in tumours to enhance therapeutic efficacy and minimize the damage to surrounding tissues.
Collapse
Affiliation(s)
- Huaiyong Xing
- State Key Laboratory of High performance Ceramics and Superfine Microstructures, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Ding Y, Li S, Nie G. Nanotechnological strategies for therapeutic targeting of tumor vasculature. Nanomedicine (Lond) 2014; 8:1209-22. [PMID: 23837858 DOI: 10.2217/nnm.13.106] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Neovascularization plays fundamental roles in tumor growth and metastasis. Tumor blood vessels are highly accessible and express various angiogenic markers that are either not present or are expressed at low levels in normal vessels, thereby serving as favorable targets for cancer therapy. Cancer nanotechnology, as an integrated platform, offers great opportunities for optimizing drug efficacy and pharmacokinetics while reducing side effects. Nanoparticles with tunable size, shape and surface modification have been exploited to achieve effective tumor vascular targeting. Here, we briefly introduce the signatures of tumor neovascularization and the review investigations on vascular-targeted anti-tumor nanomedicines. We also provide our perspectives on the promising fields of combination therapy and theranostic nanomedicines, as well as the challenges of nanotechnology-based cancer therapy. Furthermore, introducing new functionality would significantly consolidate the current development of nanomaterials based on tumor vasculature targeting.
Collapse
Affiliation(s)
- Yanping Ding
- CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, National Center for Nanoscience & Technology of China, Beijing, China
| | | | | |
Collapse
|
17
|
Misra SK, Kondaiah P, Bhattacharya S, Boturyn D, Dumy P. Co-liposomes comprising a lipidated multivalent RGD-peptide and a cationic gemini cholesterol induce selective gene transfection in αvβ3 and αvβ5 integrin receptor-rich cancer cells. J Mater Chem B 2014; 2:5758-5767. [DOI: 10.1039/c4tb00701h] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Palmitoylated-RGD4 mediated gene transfer and cell targeting using a cationic gemini cholesterol based liposome.
Collapse
Affiliation(s)
- Santosh K. Misra
- Department of Organic Chemistry
- Indian Institute of Science
- Bangalore 560 012, India
| | - Paturu Kondaiah
- Department of Molecular Reproduction
- Development and Genetics
- Indian Institute of Science
- Bangalore 560 012, India
| | - Santanu Bhattacharya
- Department of Organic Chemistry
- Indian Institute of Science
- Bangalore 560 012, India
- JNCASR
- Bangalore 560 064, India
| | - Didier Boturyn
- Univ Grenoble Alpes
- Département de Chimie Moléculaire
- 38400 Grenoble, France
- CNRS
- UMR 5250
| | - Pascal Dumy
- CNRS
- UMR 5250
- , France
- IBMM-UMR-5247 Ecole Nationale Supérieure de Chimie de Montpellier
- 34296 Montpellier cedex 5, France
| |
Collapse
|
18
|
Liu B, Feng Y, Zhang JY, Li HM, Li XD, Jia HL, Li ZY, Feng J. Imaging of bronchioloalveolar carcinoma in the mice with the αⅤβ3 integrin-targeted tracer (99m)Tc-RGD-4CK. Transl Res 2013; 162:174-80. [PMID: 23867618 DOI: 10.1016/j.trsl.2013.06.006] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/09/2013] [Revised: 06/25/2013] [Accepted: 06/29/2013] [Indexed: 12/22/2022]
Abstract
Receptor-based imaging agents have shown improved specificity and sensitivity of cancer diagnosis by targeting the specific features of cancer. Here we reported the (99m)Tc-labeling of a cyclic polypeptide RGD-4CK and the characterization of this agent in vitro and in bronchioloalveolar carcinoma (BAC) xenograft model. The αⅤβ3 integrin receptor binding affinity of (99m)Tc-RGD-4CK was determined in BAC. The cancer targeting properties of (99m)Tc-RGD-4CK were determined in NCI-H358 xenografted nude mice. Moreover, the BAC uptake of (99m)Tc-RGD-4CK was blocked with nonradiolabeled RGD-4CK in xenografts. The competitive assay showed that (99m)Tc-RGD-4CK exhibited high specificity to BAC cell line NCI-H358. Biodistribution studies indicated that (99m)Tc-RGD-4CK exhibited high tumor uptake (4.12 ± 1.21% injected dose/g 120 minutes after injection) and prolonged tumor retention (2.08 ± 0.33% injected dose/g 240 minutes after injection) in NCI-H358 xenografted nude mice. Moreover, (99m)Tc-RGD-4CK produced a good tumor-to-lung ratio (2.38) because of low lung activity accumulation 120 minutes postinjection. BAC on the flank of xenografted mice was clearly visualized by single photon emission computed tomography/computed tomography imaging using (99m)Tc-RGD-4CK. In conclusion, this study provides evidence that (99m)Tc-RGD-4CK is a promising agent for noninvasive determination of αⅤβ3 integrin status and therapy monitoring in BAC.
Collapse
Affiliation(s)
- Bin Liu
- Department of Nuclear Medicine, The Second Affiliated Hospital of Hebei Medical University, Shijiazhuang, China
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Marelli UK, Rechenmacher F, Sobahi TRA, Mas-Moruno C, Kessler H. Tumor Targeting via Integrin Ligands. Front Oncol 2013; 3:222. [PMID: 24010121 PMCID: PMC3757457 DOI: 10.3389/fonc.2013.00222] [Citation(s) in RCA: 165] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2013] [Accepted: 08/13/2013] [Indexed: 01/02/2023] Open
Abstract
Selective and targeted delivery of drugs to tumors is a major challenge for an effective cancer therapy and also to overcome the side-effects associated with current treatments. Overexpression of various receptors on tumor cells is a characteristic structural and biochemical aspect of tumors and distinguishes them from physiologically normal cells. This abnormal feature is therefore suitable for selectively directing anticancer molecules to tumors by using ligands that can preferentially recognize such receptors. Several subtypes of integrin receptors that are crucial for cell adhesion, cell signaling, cell viability, and motility have been shown to have an upregulated expression on cancer cells. Thus, ligands that recognize specific integrin subtypes represent excellent candidates to be conjugated to drugs or drug carrier systems and be targeted to tumors. In this regard, integrins recognizing the RGD cell adhesive sequence have been extensively targeted for tumor-specific drug delivery. Here we review key recent examples on the presentation of RGD-based integrin ligands by means of distinct drug-delivery systems, and discuss the prospects of such therapies to specifically target tumor cells.
Collapse
Affiliation(s)
- Udaya Kiran Marelli
- Institute for Advanced Study (IAS) and Center for Integrated Protein Science (CIPSM), Department Chemie, Technische Universität München , Garching , Germany
| | | | | | | | | |
Collapse
|
20
|
Yewale C, Baradia D, Vhora I, Misra A. Proteins: emerging carrier for delivery of cancer therapeutics. Expert Opin Drug Deliv 2013; 10:1429-48. [DOI: 10.1517/17425247.2013.805200] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
21
|
Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells. J Control Release 2012; 165:110-8. [PMID: 23159529 DOI: 10.1016/j.jconrel.2012.11.007] [Citation(s) in RCA: 75] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2012] [Revised: 11/05/2012] [Accepted: 11/10/2012] [Indexed: 11/21/2022]
Abstract
A novel, EGFR-targeted nanomedicine has been developed in the current study. Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864-L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment. Albumin nanoparticles were surface-coated with bifunctional polyethylene glycol 3500 (PEG) and a nanobody-the single variable domain of an antibody-(Ega1) against the epidermal growth factor receptor (EGFR). EGa1-PEG functionalized nanoparticles showed a 40-fold higher binding to EGFR-positive 14C squamous head and neck cancer cells in comparison to PEGylated nanoparticles. 17864-L(x) loaded EGa1-PEG nanoparticles were internalized by clathrin-mediated endocytosis and ultimately digested in lysosomes. The intracellular routing of EGa1 targeted nanoparticles leads to a successful release of the kinase inhibitor in the cell and inhibition of proliferation whereas the non-targeted formulations had no antiproliferative effects on 14C cells. The drug loaded targeted nanoparticles were as effective as the free drug in vitro. These results demonstrate that multikinase inhibitor loaded nanoparticles are interesting nanomedicines for the treatment of EGFR-positive cancers.
Collapse
|
22
|
Davies-Venn CA, Angermiller B, Wilganowski N, Ghosh P, Harvey BR, Wu G, Kwon S, Aldrich MB, Sevick-Muraca EM. Albumin-binding domain conjugate for near-infrared fluorescence lymphatic imaging. Mol Imaging Biol 2012; 14:301-14. [PMID: 21688052 PMCID: PMC3346932 DOI: 10.1007/s11307-011-0499-x] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
PURPOSE The aim of this study was to develop and characterize a novel peptide imaging agent for noninvasive near-infrared fluorescence imaging of protein transport by the lymphatics. An imaging agent consisting of a cyclic albumin-binding domain (cABD) peptide, with sequence, Arg-Leu-Ile-Glu-Asp-Ile-Cys-Leu-Pro-Arg-Trp-Gly-Cys-Leu-Trp-Glu-Asp-Asp-Lys, was conjugated to a near-infrared fluorophore, IRDye800CW, allowing for enhanced vascular uptake, retention, and fluorescence imaging. PROCEDURE Characterization of the cABD-IRDye800 peptide conjugate was performed using fluorescence spectroscopy to assess optical properties and SDS-PAGE and Biacore binding assays to determine binding affinity and specificity. Fluorescence imaging of normal C57BL/6 mice was conducted to monitor lymphatic uptake and retention. RESULTS cABD-IRDye800 exhibited approximately six times greater fluorescent yield and greater stability than indocyanine green, an agent previously used in humans to image lymphatic vasculature. The agent exhibited affinity for albumin with IC(50) and Kd in the nanomolar range and demonstrated superior retention characteristics within mouse lymphatics when compared with IRDye800CW. CONCLUSIONS cABD-IRDye800 has utility for assessing lymphatic function in mouse models of human lymphatic disease and the potential for use in clinical diagnostic imaging of the lymphatic vasculature.
Collapse
Affiliation(s)
- Cynthia A. Davies-Venn
- The Center for Molecular Imaging, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, 1825 Pressler Street, SRB 330A, Houston, TX 77030 USA
- Translational Biology and Molecular Medicine Program, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030 USA
| | - Bonnie Angermiller
- The Center for Molecular Imaging, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, 1825 Pressler Street, SRB 330A, Houston, TX 77030 USA
| | - Nathaniel Wilganowski
- The Center for Molecular Imaging, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, 1825 Pressler Street, SRB 330A, Houston, TX 77030 USA
| | - Pradip Ghosh
- The Center for Molecular Imaging, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, 1825 Pressler Street, SRB 330A, Houston, TX 77030 USA
| | - Barrett R. Harvey
- The Center for Immunology and Autoimmune Diseases, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, 1825 Pressler St. SRB 330A, Houston, TX 77030 USA
| | - Grace Wu
- The Center for Molecular Imaging, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, 1825 Pressler Street, SRB 330A, Houston, TX 77030 USA
| | - Sunkuk Kwon
- The Center for Molecular Imaging, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, 1825 Pressler Street, SRB 330A, Houston, TX 77030 USA
| | - Melissa B. Aldrich
- The Center for Molecular Imaging, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, 1825 Pressler Street, SRB 330A, Houston, TX 77030 USA
| | - Eva M. Sevick-Muraca
- The Center for Molecular Imaging, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, 1825 Pressler Street, SRB 330A, Houston, TX 77030 USA
| |
Collapse
|
23
|
Cho H, Balaji S, Sheikh AQ, Hurley JR, Tian YF, Collier JH, Crombleholme TM, Narmoneva DA. Regulation of endothelial cell activation and angiogenesis by injectable peptide nanofibers. Acta Biomater 2012; 8:154-64. [PMID: 21925628 DOI: 10.1016/j.actbio.2011.08.029] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2011] [Revised: 08/12/2011] [Accepted: 08/31/2011] [Indexed: 11/17/2022]
Abstract
RAD16-II peptide nanofibers are promising for vascular tissue engineering and were shown to enhance angiogenesis in vitro and in vivo, although the mechanism remains unknown. We hypothesized that the pro-angiogenic effect of RAD16-II results from low-affinity integrin-dependent interactions of microvascular endothelial cells (MVECs) with RAD motifs. Mouse MVECs were cultured on RAD16-II with or without integrin and MAPK/ERK pathway inhibitors, and angiogenic responses were quantified. The results were validated in vivo using a mouse diabetic wound healing model with impaired neovascularization. RAD16-II stimulated spontaneous capillary morphogenesis, and increased β(3) integrin phosphorylation and VEGF expression in MVECs. These responses were abrogated in the presence of β(3) and MAPK/ERK pathway inhibitors or on the control peptide without RAD motifs. Wide-spectrum integrin inhibitor echistatin completely abolished RAD16-II-mediated capillary morphogenesis in vitro and neovascularization and VEGF expression in the wound in vivo. The addition of the RGD motif to RAD16-II did not change nanofiber architecture or mechanical properties, but resulted in significant decrease in capillary morphogenesis. Overall, these results suggest that low-affinity non-specific interactions between cells and RAD motifs can trigger angiogenic responses via phosphorylation of β(3) integrin and MAPK/ERK pathway, indicating that low-affinity sequences can be used to functionalize biocompatible materials for the regulation of cell migration and angiogenesis, thus expanding the current pool of available motifs that can be used for such functionalization. Incorporation of RAD or similar motifs into protein engineered or hybrid peptide scaffolds may represent a novel strategy for vascular tissue engineering and will further enhance design opportunities for new scaffold materials.
Collapse
Affiliation(s)
- Hongkwan Cho
- School of Energy, Environmental, Biological, and Medical Engineering, University of Cincinnati, Cincinnati, OH 45221, USA
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release 2011; 157:168-82. [PMID: 21839127 DOI: 10.1016/j.jconrel.2011.07.031] [Citation(s) in RCA: 928] [Impact Index Per Article: 71.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2011] [Accepted: 07/20/2011] [Indexed: 10/17/2022]
Abstract
Albumin, a versatile protein carrier for drug delivery, has been shown to be nontoxic, non-immunogenic, biocompatible and biodegradable. Therefore, it is ideal material to fabricate nanoparticles for drug delivery. Albumin nanoparticles have gained considerable attention owing to their high binding capacity of various drugs and being well tolerated without any serious side-effects. The current review embodies an in-depth discussion of albumin nanoparticles with respect to types, formulation aspects, major outcomes of in vitro and in vivo investigations as well as site-specific drug targeting using various ligands modifying the surface of albumin nanoparticles with special insights to the field of oncology. Specialized nanotechnological techniques like desolvation, emulsification, thermal gelation and recently nano-spray drying, nab-technology and self-assembly that have been investigated for fabrication of albumin nanoparticles, are also discussed. Nanocomplexes of albumin with other components in the area of drug delivery are also included in this review.
Collapse
Affiliation(s)
- Ahmed O Elzoghby
- Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, El-Khartoum Square, Azarita, Alexandria 21521, Egypt.
| | | | | |
Collapse
|
25
|
Yang T, Wang Y, Li Z, Dai W, Yin J, Liang L, Ying X, Zhou S, Wang J, Zhang X, Zhang Q. Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2011; 8:81-92. [PMID: 21664295 DOI: 10.1016/j.nano.2011.05.003] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/24/2010] [Revised: 04/15/2011] [Accepted: 05/03/2011] [Indexed: 12/12/2022]
Abstract
UNLABELLED The present study demonstrates the applicability of a novel strategy that employs targeted delivery of combined treatment against tumor neovasculature. Briefly, a ligand of integrins, cyclic arginine-glycine-aspartic acid-tyrosine-lysine pentapeptide (cRGDyK), was conjugated to the PEG end of polyethylene glycol-b-poly lactic acid (PEG-b-PLA), and doxorubicin was chemically linked to the PLA end of PEG-b-PLA. The targeted dual-drug micelle system was prepared by mixing combretastatin A4 (an antivascular agent), PEG-b-PLA, and the above two conjugates using a solution-casting method. The targeted micelles significantly enhanced cellular uptake of the drug by B16-F10 cells and human umbilical vein endothelial cells through a receptor-mediated endocytosis. The cRGDyK-modified dual-drug system achieved an optimal antitumor effect, lifespan increase, antineovasculature, antiproliferation, and apoptosis induction, revealing the advantage of active targeting and the modified combination therapy. In conclusion, the integration of targeted delivery and combination therapy against tumor neovasculature represents a promising approach for cancer treatment. FROM THE CLINICAL EDITOR A ligand of integrins was conjugated to PEG-b-PLA, and doxorubicin was chemically linked to the PLA. Efficiency was demonstrated in a cancer model. The integration of targeted delivery and combination therapy against tumor neovasculature represents a promising approach for cancer treatment.
Collapse
MESH Headings
- Animals
- Antibiotics, Antineoplastic/administration & dosage
- Antibiotics, Antineoplastic/chemistry
- Antibiotics, Antineoplastic/therapeutic use
- Antineoplastic Agents, Phytogenic/administration & dosage
- Antineoplastic Agents, Phytogenic/chemistry
- Antineoplastic Agents, Phytogenic/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols/chemistry
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Cell Line, Tumor
- Cell Proliferation/drug effects
- Doxorubicin/administration & dosage
- Doxorubicin/chemistry
- Doxorubicin/therapeutic use
- Drug Carriers/chemistry
- Drug Delivery Systems
- Human Umbilical Vein Endothelial Cells
- Humans
- Lactates/chemistry
- Lactates/therapeutic use
- Melanoma, Experimental
- Mice
- Mice, Inbred C57BL
- Micelles
- Neovascularization, Pathologic/drug therapy
- Peptides, Cyclic/chemistry
- Peptides, Cyclic/therapeutic use
- Polyethylene Glycols/chemistry
- Polyethylene Glycols/therapeutic use
- Stilbenes/administration & dosage
- Stilbenes/chemistry
- Stilbenes/therapeutic use
Collapse
Affiliation(s)
- Tingyuan Yang
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|